Hosted on MSN2mon
Jacobio’s KRAS Inhibitor Glecirasib Shows Promising Trial ResultsIts research pipeline targets six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC, with the aim of becoming a global leader in drug research and development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback